PharmaTher Holdings Ltd. (PHRM.CN)
- GlobeNewswire
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine productsSupports commercializing novel uses and delivery methods of psychedelics TORONTO, July 21, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining a novel formulation of
- GlobeNewswire
PharmaTher To Participate in Grizzle Psychedelics Con
TORONTO, June 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will participate in the Grizzle Psychedelics Con today at 12 PM ET. “I am very excited to participate in this one-of-a-kind virtual investor conference made possible by Grizzle Media, who has built an amazing platform and dedicated following of institutional and
- GlobeNewswire
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
TORONTO, June 16, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. The corporate presentation will be available on-demand starting at 7:00 am ET. For more information about this event and to attend, visit: https:
